Diabetes News January 21st 2011

Randomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery)
Basal bolus treatment with glargine once daily plus glulisine before meals improved glycemic control and reduced hospital complications compared with SSI in general surgery patients. Our study indicates that a basal bolus insulin regimen is preferred over SSI in the hospital management of general surgery patients with type 2 diabetes (Diabetes Care)

The Burden of Hypoglycemia in Type 2 Diabetes: A Systematic Review of Patient and Economic Perspectives
In light of the impact on the patient and wider society in economic as well as clinical terms, consideration of hypoglycemia should be an important part of clinical decision making (Journal of Clinical Outcomes Management)

Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes
These findings better elucidate our knowledge of diabetic glomerulopathy, beside and along with previous findings, in vivo and in vitro, on ox-LDL and FFA effects in mesangial cells (Nutrition, Metabolism & Cardiovascular Diseases)

Subcellular mechanisms of adaptation in the diabetic myocardium: Relevance to ischemic preconditioning in the nondiseased heart
The present article reviews some controversial findings of enhanced resistance to ischemia in the diabetic heart that stem from experimental studies in different models of myocardial ischemia/reperfusion injury (Experimental & Clinical Cardiology)

Insulin combined with pioglitazone: risk of cardiac failure
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain, and oedema (MHRA)

Bariatric Surgery Reduces the Need for Glycemic Control Medications and Related Health Care Costs
Bariatric surgery is associated with a large reduction in the use of medication for glycemic control and with lower postsurgical health care costs (Clinical Diabetes)

Incentivising wellness: improving the treatment of long-term conditions
This report shows how the NHS can save tens of billions of pounds while also taking better care of one of the UK’s fastest-growing diseases – diabetes (Policy Exchange)

Type 2 diabetes genetic association database manually curated for the study design and odds ratio
This database can be used for research purposes, such as an association and functional study of type 2 diabetes related genes, and as a primary genetic resource to construct a diabetes risk test in the preparation of personalized medicine in the future (BioMed Central)

Novo Nordisk’s new pen for children – NovoPen Echo(R) – wins GOOD DESIGN(TM) Award
Judging is made based on product design which is new, visionary and innovative and that may enrich people’s lives (Novo Nordisk)

Galway and US firms team up on inhaled insulin product
Aerogen, an aerosol drug delivery company based in Galway, has announced a drug-delivery partnership with Dance Pharmaceuticals, a biotech company in San Francisco, California, to develop a next-generation inhaled insulin product (Silicon Republic)

FDA Requests More Trials for Mannkind Insulin
MannKind Chairman and CEO Alfred Mann said in a statement they were disappointed by the FDA response but encouraged that the agency was asking for studies only to confirm bridging and handling of the next-generation inhaler (PharmaLive)